标题
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
作者
关键词
-
出版物
Frontiers in Oncology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-07-31
DOI
10.3389/fonc.2018.00287
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The role of JAK2 inhibitors in MPNs 7 years after approval
- (2018) Francesco Passamonti et al. BLOOD
- An Update on JAK Inhibitors
- (2018) Francesca Musumeci et al. CURRENT MEDICINAL CHEMISTRY
- Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms
- (2018) Qing-Yun Wu et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR
- (2016) Miguel Waterhouse et al. ANNALS OF HEMATOLOGY
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Influence of platelet-activating factor receptor (PAFR) on Brucella abortus infection: implications for manipulating the phagocytic strategy of B. abortus
- (2016) Jin Ju Lee et al. BMC MICROBIOLOGY
- Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
- (2016) Laura Quick et al. CANCER RESEARCH
- Baricitinib for the treatment of rheumatoid arthritis
- (2016) Satoshi Kubo et al. Expert Review of Clinical Immunology
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- AG490 suppresses EPO-mediated activation of JAK2-STAT but enhances blood flow recovery in rats with critical limb ischemia
- (2016) Han-Tan Chai et al. Journal of Inflammation-London
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- (2016) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
- (2015) A. L. Wong et al. ANNALS OF ONCOLOGY
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo
- (2015) P. Yue et al. CANCER RESEARCH
- Biology of IL-27 and its Role in the Host Immunity against Mycobacterium Tuberculosis
- (2015) Abualgasim Elgaili Abdalla et al. International Journal of Biological Sciences
- Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F
- (2015) Brady L. Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group
- (2015) Valentin Goede et al. LEUKEMIA & LYMPHOMA
- A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
- (2015) Annette E. Hay et al. LEUKEMIA & LYMPHOMA
- A Big Bang model of human colorectal tumor growth
- (2015) Andrea Sottoriva et al. NATURE GENETICS
- STAT1-Mediated Down-Regulation of Bcl-2 Expression Is Involved in IFN-γ/TNF-α–Induced Apoptosis in NIT-1 Cells
- (2015) Zhao-hui Cao et al. PLoS One
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer
- (2015) Min Soo Kim et al. Oncotarget
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer
- (2015) Xiaoxia Zhu et al. Frontiers in Endocrinology
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- The molecular regulation of Janus kinase (JAK) activation
- (2014) Jeffrey J. Babon et al. BIOCHEMICAL JOURNAL
- Activating STAT6 mutations in follicular lymphoma
- (2014) M. Yildiz et al. BLOOD
- Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
- (2014) Yonghe Li et al. CANCER LETTERS
- HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
- (2014) Kellie S. Rath et al. CANCER RESEARCH
- TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting
- (2014) A. Herrmann et al. CANCER RESEARCH
- The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse
- (2014) O. R. Bandapalli et al. HAEMATOLOGICA
- Interleukin-4 up-regulation of epidermal interleukin-19 expression in keratinocytes involves the binding of signal transducer and activator of transcription 6 (Stat6) to the imperfect Stat6 sites
- (2014) Lei Bao et al. IMMUNOLOGY
- Autocrine Regulation of IL-21 Production in Human T Lymphocytes
- (2014) F. Caprioli et al. JOURNAL OF IMMUNOLOGY
- JAK2-STAT3 Blockade by AG490 Suppresses Autoimmune Arthritis in Mice via Reciprocal Regulation of Regulatory T Cells and Th17 Cells
- (2014) J.-S. Park et al. JOURNAL OF IMMUNOLOGY
- Interleukin-21: a double-edged sword with therapeutic potential
- (2014) Rosanne Spolski et al. NATURE REVIEWS DRUG DISCOVERY
- Structural basis of recognition of interferon-α receptor by tyrosine kinase 2
- (2014) Heidi J A Wallweber et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma
- (2014) Q. Zheng et al. NEURO-ONCOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
- (2014) D Zhao et al. ONCOGENE
- Functional Polymorphisms in Interleukin-23 Receptor and Susceptibility to Esophageal Squamous Cell Carcinoma in Chinese Population
- (2014) Bin Ni et al. PLoS One
- Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
- (2014) A. J. Brooks et al. SCIENCE
- STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma
- (2014) Qu Zhang et al. TUMOR BIOLOGY
- Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids
- (2013) Hongliang Li et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Therapeutic Targeting of the JAK/STAT Pathway
- (2013) Saara Aittomäki et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- TransientJAK2V617F mutation in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone
- (2013) Stephen E. Langabeer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα+ tumorigenesis
- (2013) S R Chan et al. CELL DEATH AND DIFFERENTIATION
- Molecular Pathways: Adiponectin and Leptin Signaling in Cancer
- (2013) M. N. VanSaun CLINICAL CANCER RESEARCH
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia
- (2013) D Bellanger et al. LEUKEMIA
- Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
- (2013) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
- (2013) El-ad David Amir et al. NATURE BIOTECHNOLOGY
- EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors
- (2013) J Wu et al. ONCOGENE
- AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
- (2013) E. R. Plimack et al. ONCOLOGIST
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Estrogens Regulate the Hepatic Effects of Growth Hormone, a Hormonal Interplay with Multiple Fates
- (2013) Leandro Fernández-Pérez et al. Frontiers in Endocrinology
- Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression
- (2012) Kiyotaka Yokogami et al. Brain Tumor Pathology
- Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells
- (2012) Karolina Swiatek-Machado et al. CANCER BIOLOGY & THERAPY
- The Permeability of Reconstituted Nuclear Pores Provides Direct Evidence for the Selective Phase Model
- (2012) Bastian B. Hülsmann et al. CELL
- Therapeutic Strategies for Harnessing Human Eosinophils in Allergic Inflammation, Hypereosinophilic Disorders, and Cancer
- (2012) Zhaleh J. Amini-Vaughan et al. CURRENT ALLERGY AND ASTHMA REPORTS
- STAT6-dependent and -independent mechanisms in Th2 polarization
- (2012) Elisabeth Maier et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer
- (2012) M. M. Seavey et al. MOLECULAR CANCER THERAPEUTICS
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- The composition and signaling of the IL-35 receptor are unconventional
- (2012) Lauren W Collison et al. NATURE IMMUNOLOGY
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
- (2012) D W Kufe ONCOGENE
- JAK2 the future: therapeutic strategies for JAK-dependent malignancies
- (2012) Lindsay M. LaFave et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The JAK/STAT Pathway
- (2012) D. A. Harrison Cold Spring Harbor Perspectives in Biology
- First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
- (2012) Malabika Sen et al. Cancer Discovery
- A pathway map of prolactin signaling
- (2012) Aneesha Radhakrishnan et al. Journal of Cell Communication and Signaling
- Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo
- (2011) Zuo-Wen Liang et al. ASIAN JOURNAL OF ANDROLOGY
- Toll-like Receptor 4 Variant D299G Induces Features of Neoplastic Progression in Caco-2 Intestinal Cells and Is Associated With Advanced Human Colon Cancer
- (2011) Annette Eyking et al. GASTROENTEROLOGY
- Heterogeneity in breast cancer
- (2011) Kornelia Polyak JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models
- (2011) Yunguang Sun et al. Journal of Thoracic Oncology
- TLR4 knockout protects mice from radiation-induced thymic lymphoma by downregulation of IL6 and miR-21
- (2011) C Liu et al. LEUKEMIA
- The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
- (2011) Daniela Ungureanu et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Phosphorylation of JAK2 by serotonin 5-HT2A receptor activates both STAT3 and ERK1/2 pathways and increases growth of JEG-3 human placental choriocarcinoma cell
- (2011) T. Oufkir et al. PLACENTA
- Simultaneous siRNA Targeting of Src and Downstream Signaling Molecules Inhibit Tumor Formation and Metastasis of a Human Model Breast Cancer Cell Line
- (2011) Jeffrey D. Bjorge et al. PLoS One
- MicroRNAs and STAT interplay
- (2011) Gary Kohanbash et al. SEMINARS IN CANCER BIOLOGY
- TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients
- (2010) Chao Wang et al. BMC CANCER
- Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification
- (2010) A. A. Dudka et al. CANCER RESEARCH
- IFN Induces miR-21 through a Signal Transducer and Activator of Transcription 3-Dependent Pathway as a Suppressive Negative Feedback on IFN-Induced Apoptosis
- (2010) C. H. Yang et al. CANCER RESEARCH
- Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor
- (2010) Ken Miyoshi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Stat5 Promotes Survival of Mammary Epithelial Cells through Transcriptional Activation of a Distinct Promoter in Akt1
- (2010) B. A. Creamer et al. MOLECULAR AND CELLULAR BIOLOGY
- AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells
- (2010) J. Yang et al. MOLECULAR CANCER THERAPEUTICS
- Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
- (2010) F. Baffert et al. MOLECULAR CANCER THERAPEUTICS
- STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer
- (2010) Dimitrios Iliopoulos et al. MOLECULAR CELL
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
- (2010) Stephen T Oh et al. Expert Review of Hematology
- Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocytes
- (2009) Raghunatha R. Yammani et al. ARTHRITIS AND RHEUMATISM
- Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
- (2009) F. P. S. Santos et al. BLOOD
- Impaired development of human Th1 cells in patients with deficient expression of STAT4
- (2009) H.-C. Chang et al. BLOOD
- Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
- (2009) Marcin Kortylewski et al. CANCER CELL
- Targeting the JAK2/STAT3 axis in Alzheimer's disease
- (2009) Tomohiro Chiba et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer
- (2009) Rao INTERNATIONAL JOURNAL OF ONCOLOGY
- Molecular Mechanism for SHP2 in Promoting HER2-induced Signaling and Transformation
- (2009) Xiangdong Zhou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Stat3 promotes directional cell migration by regulating Rac1 activity via its activator PIX
- (2009) T. S. Teng et al. JOURNAL OF CELL SCIENCE
- IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
- (2009) Lin Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease
- (2009) A. Andoh et al. JOURNAL OF IMMUNOLOGY
- SOCS1 Links Cytokine Signaling to p53 and Senescence
- (2009) Viviane Calabrese et al. MOLECULAR CELL
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium
- (2009) Hui Gao et al. STEM CELLS
- Mucin-interacting proteins: from function to therapeutics
- (2009) Shantibhusan Senapati et al. TRENDS IN BIOCHEMICAL SCIENCES
- IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis
- (2008) R H Fontaine et al. CELL DEATH AND DIFFERENTIATION
- Structures and biological functions of IL-31 and IL-31 receptors
- (2008) Qing Zhang et al. CYTOKINE & GROWTH FACTOR REVIEWS
- IFNγ signaling—Does it mean JAK–STAT?
- (2008) Daniel J. Gough et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Leptin signaling in breast cancer: An overview
- (2008) Donatella Cirillo et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
- (2008) Maciej Kujawski et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Growth hormone receptor modulators
- (2008) Vita Birzniece et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Canonical and non-canonical JAK–STAT signaling
- (2008) Willis X. Li TRENDS IN CELL BIOLOGY
- Regulation of XAF1 expression in human colon cancer cell by interferon β: Activation by the transcription regulator STAT1
- (2007) Yunwei Sun et al. CANCER LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More